TLIS — Talis Biomedical Income Statement
0.000.00%
Last trade - 00:00- $2.92m
- -$56.95m
- $2.13m
- 47
- 39
- 26
- 30
Annual income statement for Talis Biomedical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 3.98 | 10.9 | 8.19 | 4.81 | 2.13 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | -3.58 | 2.09 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 30.7 | 102 | 200 | 120 | 68.9 |
| Operating Profit | -26.7 | -91.2 | -192 | -115 | -66.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -27.5 | -91.1 | -192 | -113 | -62 |
| Net Income After Taxes | -27.5 | -91.1 | -192 | -113 | -62 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -27.5 | -91.1 | -192 | -113 | -62 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 26.4 | -91.1 | -192 | -113 | -62 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 16.9 | -58.2 | -127 | -61.6 | -32.6 |
| Dividends per Share |